• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025.

    Key Financial Results

    Third Quarter 2025 vs. Third Quarter 2024

    • Net sales of $214 million versus $200 million, representing 7% year-over-year growth.
    • Net loss of -$6.5 million versus net earnings of $10.6 million.
    • Diluted EPS of -$0.36 as compared with $0.56.
    • Adjusted diluted EPS(1) of -$0.15 as compared with $0.56.
    • Adjusted EBITDA(2) of $13.8 million versus $24.6 million.
    • Direct selling Active Customers of 388,000 versus 452,000.
    • Hiya Active Monthly Subscribers of 193,400.

    Q3 2025 Financial Performance

    Consolidated Results

     

    Year-Over-Year

    Sequentially

    Net Sales

    $214 million

    +7% (No meaningful FX impact)

    -9%

    Net (Loss) Earnings*

    -$6.5 million

    N/A

    N/A

    Diluted EPS

    -$0.36

    N/A

    N/A

    Adjusted Diluted EPS(1)

    -$0.15

    N/A

    N/A

    Adjusted EBITDA(2)

    $13.8 million

    -44%

    -55%

    *Pretax earnings for Q3 2025 totaled $1.8 million with income tax expense of $8.5 million. The adjustment to income taxes during the period, as a result of updating the annual effective tax rate, is about $7.6 million greater than what would have been expected using the previously guided 45% tax rate.

    Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.

    "USANA provided third quarter results in line with the preliminary results we announced on October 9, 2025," said Jim Brown, President and Chief Executive Officer. "We rolled out our enhanced Brand Partner compensation plan during the third quarter. Since this launch, our commercial team has been actively training, educating and supporting Brand Partners across our global markets to help them leverage the new plan. We are encouraged by the pickup in sales activity and leader productivity in recent weeks. Our enhanced compensation plan represents a bold and strategic move to modernize our business and better position our Brand Partners, and the Company, for long-term success in a competitive landscape.

    "We held a successful Global Convention in Salt Lake City during the third quarter where we launched several new and upgraded products, recognized our Brand Partners, and trained them on our enhanced compensation plan. Our commercial team will continue to work alongside our Brand Partners over the next several quarters to help promote our new products and compensation plan. We remain confident that our product and opportunity strategy will position the Company to drive growth in our direct selling business and deliver long-term value for our stakeholders.

    "Hiya, our direct-to-consumer (DTC) business, has delivered 26% year-to-date sales growth, and made significant progress on several integration initiatives during the quarter, including the transition to a new logistics partner, which is anticipated to drive operational efficiency. We are also leveraging USANA's manufacturing expertise to support Hiya and will begin bringing their products in-house over the next several months. We continue to expect Hiya to generate double-digit sales growth for 2025 and remain confident in their long-term growth."

    Q3 2025 Direct Selling Regional Results:

    Asia Pacific Region

     

    Year-Over-Year

    Year-Over-Year

    (Constant Currency)

    Sequentially

    Net Sales

    $140 million

    -13%

    -13%

    -15%

    Active Customers

    308,000

    -14%

    N/A

    -8%

    Asia Pacific Sub-Regions

     

     

    Year-Over-Year

    Year-Over-Year

    (Constant Currency)

    Sequentially

    Greater China

    Net Sales

    $93 million

    -9%

    No meaningful FX impact

    -18%

    Active

    210,000

    -14%

    N/A

    -9%

    Customers

    North Asia

    Net Sales

    $18 million

    -14%

    -12%

    +3%

    Active

    37,000

    -10%

    N/A

    —%

    Customers

    Southeast Asia Pacific

    Net Sales

    $29 million

    -22%

    -23%

    -11%

    Active

    61,000

    -20%

    N/A

    -10%

    Customers

    Americas and Europe Region

     

     

    Year-Over-Year

    Year-Over-Year

    (Constant Currency)

    Sequentially

    Net Sales*

    $43 million

    +8%

    +8%

    +12%

    Active Customers

    80,000

    -13%

    N/A

    -2%

    *Includes $7 million of ‘Other'

    Q3 2025 Hiya Direct to Consumer Results:

    Hiya

    Net Sales

    $31 million

    Active Monthly Subscribers

    193,400

    Balance Sheet

    The Company ended the quarter with $145 million in cash and cash equivalents and no debt. The Company has approximately $34 million remaining under the current share repurchase authorization as of the end of the third quarter.

    Fiscal Year 2025 Outlook

    The Company is updating its outlook for fiscal year 2025, as follows:

    Fiscal Year 2025 Outlook

     

    Updated Estimate

    Previous Range

    Consolidated net sales

    $920 million

    $920 million to $1.0 billion

    Net earnings

    $15 million

    $29 million to $41 million

    Diluted EPS

    $0.78

    $1.50 to $2.20

    Adjusted Diluted EPS(1)

    $1.73

    $2.35 to $3.00

    Adjusted EBITDA(2)

    $98 million

    $107 million to $123 million

    Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.

    Doug Hekking, Chief Financial Officer, commented, "Short-term profitability was burdened during the third quarter due to softer than anticipated sales, meaningful investments to support the roll out of our enhanced Brand Partner compensation plan, and a change in the estimated annual effective income tax rate that disproportionately impacted the current year quarter. Specifically, lower than expected earnings coupled with the concentration of operating and administrative expenses in the United States resulted in a meaningful increase in the annualized effective income tax rate in the third quarter from 45% to 65%. The adjustment was approximately $7.6 million greater than what would have been expected using the previously guided 45% tax rate.

    "Our revised outlook reflects modest sequential improvement in both our direct sales and DTC businesses, albeit from a lower customer base as a result of third quarter performance. We have initiated and are executing a comprehensive process to align all costs throughout the business globally with our current level of sales. As a result of this realignment and rightsizing process, we expect to incur an estimated one-time charge of $4.7 million in the fourth quarter, which is reflected in our updated outlook. We will provide an update on this process, including the actual charge, when we report our fourth quarter and full-year results early next year."

    The Company's fiscal 2025 outlook reflects:

    • Net sales from the direct selling business of approximately $788 million;
    • Net sales from Hiya of approximately $132 million, reflecting year-over-year growth of 16%;
    • Fiscal 2025 is a 53-week year and includes one additional week of sales compared to fiscal 2024. Prior to 2025, the last 53-week year was in fiscal 2020.

    ____________________

    (1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    (2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    Non-GAAP Financial Measures

    This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

    Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

    Adjusted diluted earnings per share (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.

    Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted earnings per share. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

    Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP)

    (in thousands)

     

     

     

    Quarter Ended

     

    Nine months ended

     

     

    September 27, 2025

     

    September 28, 2024

     

    September 27, 2025

     

    September 28, 2024

     

     

     

     

     

     

     

     

     

    Net earnings (loss) attributable to USANA (GAAP)

     

    $

    (6,522

    )

     

    $

    10,607

     

     

    $

    12,535

     

     

    $

    37,576

     

    Net earnings (loss) attributable to noncontrolling interest

     

     

    (140

    )

     

     

    —

     

     

     

    537

     

     

     

    —

     

    Net earnings (loss)

     

    $

    (6,662

    )

     

    $

    10,607

     

     

    $

    13,072

     

     

    $

    37,576

     

     

     

     

     

     

     

     

     

     

    Adjustments:

     

     

     

     

     

     

     

     

    Income taxes

     

    $

    8,456

     

     

    $

    8,001

     

     

    $

    24,278

     

     

    $

    28,346

     

    Interest (income) expense

     

     

    (529

    )

     

     

    (3,093

    )

     

     

    (1,201

    )

     

     

    (8,429

    )

    Depreciation and amortization

     

     

    5,112

     

     

     

    5,559

     

     

     

    16,050

     

     

     

    16,345

     

    Amortization of intangible assets - Hiya

     

     

    4,455

     

     

     

    —

     

     

     

    13,366

     

     

     

    —

     

    Earnings before interest, taxes, depreciation, and amortization (EBITDA)

     

    $

    10,832

     

     

    $

    21,074

     

     

    $

    65,565

     

     

    $

    73,838

     

     

     

     

     

     

     

     

     

     

    Add EBITDA adjustments:

     

     

     

     

     

     

     

     

    Non-cash share-based compensation

     

     

    3,576

     

     

     

    3,542

     

     

     

    10,078

     

     

     

    10,945

     

    Transaction, integration and transition costs - Hiya

     

     

    179

     

     

     

    —

     

     

     

    871

     

     

     

    —

     

    Inventory step-up - Hiya

     

     

    —

     

     

     

    —

     

     

     

    1,126

     

     

     

    —

     

    Consolidated adjusted EBITDA

     

     

    14,587

     

     

     

    24,616

     

     

     

    77,640

     

     

     

    84,783

     

    Less: Adjusted EBITDA attributable to noncontrolling interest

     

     

    (804

    )

     

     

    —

     

     

     

    (3,604

    )

     

     

    —

     

    Adjusted EBITDA attributable to USANA

     

    $

    13,783

     

     

    $

    24,616

     

     

    $

    74,036

     

     

    $

    84,783

     

     

    Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (non-GAAP)

    (in thousands, except per share data)

     

     

     

    Quarter Ended

     

    Nine months ended

     

     

    September 27, 2025

     

    September 28, 2024

     

    September 27, 2025

     

    September 28, 2024

    Net earnings (loss) attributable to USANA (GAAP)

     

    $

    (6,522

    )

     

    $

    10,607

     

    $

    12,535

     

     

    $

    37,576

     

     

     

     

     

     

     

     

     

    Earnings (loss) per common share - Diluted (GAAP)

     

    $

    (0.36

    )

     

    $

    0.56

     

    $

    0.67

     

     

    $

    1.96

    Weighted Average common shares outstanding - Diluted

     

     

    18,293

     

     

     

    19,083

     

     

    18,671

     

     

     

    19,181

     

     

     

     

     

     

     

     

     

    Adjustment to net earnings (loss):

     

     

     

     

     

     

     

     

    Transaction, integration and transition costs - Hiya

     

    $

    179

     

     

    $

    —

     

    $

    871

     

     

    $

    —

    Inventory step-up - Hiya

     

     

    —

     

     

     

    —

     

     

    1,126

     

     

     

    —

    Amortization of intangible assets - Hiya

     

     

    4,455

     

     

     

    —

     

     

    13,366

     

     

     

    —

    Adjustments to net earnings (loss) attributable to noncontrolling interest

     

     

    (941

    )

     

     

    —

     

     

    (3,066

    )

     

     

    —

    Income tax effect of adjustments to net earnings (loss)

     

     

    —

     

     

     

    —

     

     

    (4

    )

     

     

    —

    Adjusted net earnings (loss) attributable to USANA

     

    $

    (2,829

    )

     

    $

    10,607

     

    $

    24,828

     

     

    $

    37,576

     

     

     

     

     

     

     

     

     

    Adjusted earnings (loss) per common share - Diluted

     

    $

    (0.15

    )

     

    $

    0.56

     

    $

    1.33

     

     

    $

    1.96

    Weighted average common shares outstanding - Diluted

     

     

    18,293

     

     

     

    19,083

     

     

    18,671

     

     

     

    19,181

     

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Thursday, October 23, 2025 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding Hiya's growth in 2025 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2025 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with early stage operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that the Hiya acquisition disrupts each company's current plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability of to retain key personnel of Hiya; the ability to realize the benefits of the acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company with a variety of clean-label products. More information on Hiya can be found at www.hiyahealth.com.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Three Months Ended

     

     

    September 27,

    2025

     

    September 28,

    2024

     

    Net sales

    $

    213,670

     

     

    $

    200,221

     

     

    Cost of sales

     

    48,815

     

     

     

    39,257

     

     

    Gross profit

     

    164,855

     

     

     

    160,964

     

     

    Operating expenses:

     

     

     

     

    Brand Partner incentives

     

    77,684

     

     

     

    84,068

     

     

    Selling, general and administrative

     

    85,947

     

     

     

    61,295

     

     

    Total operating expenses

     

    163,631

     

     

     

    145,363

     

     

    Earnings from operations

     

    1,224

     

     

     

    15,601

     

     

    Other income (expense):

     

     

     

     

    Interest income

     

    578

     

     

     

    3,142

     

     

    Interest expense

     

    (49

    )

     

     

    (49

    )

     

    Other, net

     

    41

     

     

     

    (86

    )

     

    Other income (expense), net

     

    570

     

     

     

    3,007

     

     

    Earnings before income taxes

     

    1,794

     

     

     

    18,608

     

     

    Income taxes

     

    8,456

     

     

     

    8,001

     

     

    Net (loss) earnings

     

    (6,662

    )

     

     

    10,607

     

     

    Less: Net (loss) earnings attributable to redeemable noncontrolling interest

     

    (140

    )

     

     

    —

     

     

    Net (loss) earnings attributable to USANA

    $

    (6,522

    )

     

    $

    10,607

     

     

     

     

     

     

     

    (Loss) earnings per common share attributable to USANA

     

     

     

     

    Basic

    $

    (0.36

    )

     

    $

    0.56

     

     

    Diluted

    $

    (0.36

    )

     

    $

    0.56

     

     

     

     

     

     

     

    Weighted average common shares outstanding

     

     

     

     

    Basic

     

    18,293

     

     

     

    19,078

     

     

    Diluted

     

    18,293

     

     

     

    19,083

     

     

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    As of

    September 27,

    2025

     

    As of

    December 28,

    2024

    ASSETS

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    145,349

     

    $

    181,768

    Inventories

     

    90,781

     

     

    69,735

    Prepaid expenses and other current assets

     

    27,935

     

     

    27,684

    Total current assets

     

    264,065

     

     

    279,187

    Property and equipment, net

     

    96,212

     

     

    94,565

    Goodwill

     

    144,288

     

     

    144,168

    Intangible assets, net

     

    138,159

     

     

    151,823

    Deferred tax assets

     

    24,157

     

     

    19,644

    Other assets*

     

    59,710

     

     

    58,806

    Total assets

    $

    726,591

     

    $

    748,193

     

     

     

     

    LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    17,095

     

    $

    11,984

    Line of credit

     

    —

     

     

    23,000

    Other current liabilities

     

    101,569

     

     

    104,641

    Total current liabilities

     

    118,664

     

     

    139,625

    Deferred tax liabilities

     

    4,467

     

     

    4,073

    Other long-term liabilities

     

    21,907

     

     

    18,163

     

     

     

     

    Redeemable noncontrolling interest

     

    53,479

     

     

    54,223

     

     

     

     

    Total stockholders' equity attributable to USANA

     

    528,074

     

     

    532,109

    Total liabilities, redeemable noncontrolling interest, and stockholders' equity

    $

    726,591

     

    $

    748,193

     

    *Includes noncurrent inventories of $2,802 and $2,688 as of 27-Sep-25 and 28-Dec-24, respectively. Total inventories were $93,583 and $72,423 as of 27-Sep-25 and 28-Dec-24, respectively.

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    SALES BY REGION

    (in thousands)

    (unaudited)

     

     

    Quarter Ended

     

     

     

     

     

    September 27,

    2025

     

    September 28,

    2024

     

    Change from

    prior
    year

     

    Percent

    change

     

    Currency impact

    on sales

     

    Percent

    change

    excluding

    currency

    impact

    Direct Selling:

     

     

     

     

     

     

     

     

    Asia Pacific

     

     

     

     

     

     

     

     

    Greater China

    $

    92,571

    43.3

    %

    $

    102,261

    51.1

    %

    $

    (9,690

    )

    (9.5

    %)

    $

    504

     

    (10.0

    %)

    Southeast Asia Pacific

     

    29,178

    13.7

    %

     

    37,267

    18.6

    %

     

    (8,089

    )

    (21.7

    %)

     

    393

     

    (22.8

    %)

    North Asia

     

    17,690

    8.3

    %

     

    20,541

    10.2

    %

     

    (2,851

    )

    (13.9

    %)

     

    (403

    )

    (11.9

    %)

    Asia Pacific total

     

    139,439

    65.3

    %

     

    160,069

    79.9

    %

     

    (20,630

    )

    (12.9

    %)

     

    494

     

    (13.2

    %)

    Americas and Europe

     

    36,386

    17.0

    %

     

    38,398

    19.2

    %

     

    (2,012

    )

    (5.2

    %)

     

    72

     

    (5.4

    %)

    Direct Selling total

     

    175,825

    82.3

    %

     

    198,467

    99.1

    %

     

    (22,642

    )

    (11.4

    %)

     

    566

     

    (11.7

    %)

    Hiya

     

    30,846

    14.4

    %

     

    —

    —

    %

     

    30,846

     

    N/A

     

     

    —

     

    N/A

     

    Other

     

    6,999

    3.3

    %

     

    1,754

    0.9

    %

     

    5,245

     

    299.0

    %

     

    —

     

    299.0

    %

    Consolidated total

    $

    213,670

    100.0

    %

    $

    200,221

    100.0

    %

    $

    13,449

     

    6.7

    %

    $

    566

     

    6.4

    %

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    DIRECT SELLING ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

     

    Direct Selling Active Brand Partners by Region(1)

     

    (unaudited)

     

     

    As of

    September 27, 2025

     

    As of

    September 28, 2024

    Asia Pacific

     

     

     

     

     

     

     

     

    Greater China

     

    61,000

     

    36.3 %

     

    65,000

     

    34.6 %

    Southeast Asia Pacific

     

    43,000

     

    25.6 %

     

    52,000

     

    27.6 %

    North Asia

     

    27,000

     

    16.1 %

     

    28,000

     

    14.9 %

    Asia Pacific Total

     

    131,000

     

    78.0 %

     

    145,000

     

    77.1 %

     

     

     

     

     

     

     

     

     

    Americas and Europe

     

    37,000

     

    22.0 %

     

    43,000

     

    22.9 %

     

     

    168,000

     

    100.0 %

     

    188,000

     

    100.0 %

    Direct Selling Active Preferred Customers by Region(2)

     

    (unaudited)

     

     

    As of

    September 27, 2025

     

    As of

    September 28, 2024

    Asia Pacific

     

     

     

     

     

     

     

     

    Greater China

     

    149,000

     

    67.7 %

     

    178,000

     

    67.4 %

    Southeast Asia Pacific

     

    18,000

     

    8.2 %

     

    24,000

     

    9.1 %

    North Asia

     

    10,000

     

    4.6 %

     

    13,000

     

    4.9 %

    Asia Pacific Total

     

    177,000

     

    80.5 %

     

    215,000

     

    81.4 %

     

     

     

     

     

     

     

     

     

    Americas and Europe

     

    43,000

     

    19.5 %

     

    49,000

     

    18.6 %

     

     

    220,000

     

    100.0 %

     

    264,000

     

    100.0 %

    ______________________________

    (1)

    Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2)

    Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    OPERATING RESULTS AS A PERCENTAGE OF NET SALES

    (unaudited)

     

     

     

    Quarter Ended

     

     

    September 27, 2025

     

    September 28, 2024

     

     

    Direct selling & Other

     

    Hiya direct-to-consumer

     

    Consolidated

     

    Direct selling & Other

     

    Hiya direct-to-consumer

     

    Consolidated

    Net sales

     

    100.0%

     

    100.0%

     

    100.0%

     

    100.0%

     

    N/A

     

    100.0%

    Cost of sales

     

    20.7%

     

    35.6%

     

    22.8%

     

    19.6%

     

    N/A

     

    19.6%

    Gross profit

     

    79.3%

     

    64.4%

     

    77.2%

     

    80.4%

     

    N/A

     

    80.4%

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Brand Partner incentives

     

    42.5%

     

    —%

     

    36.4%

     

    42.0%

     

    N/A

     

    42.0%

    Selling, general and administrative

     

    35.8%

     

    66.5%

     

    40.2%

     

    30.6%

     

    N/A

     

    30.6%

    Total operating expenses

     

    78.3%

     

    66.5%

     

    76.6%

     

    72.6%

     

    N/A

     

    72.6%

    Earnings (loss) from operations

     

    1.0%

     

    (2.1)%

     

    0.6%

     

    7.8%

     

    N/A

     

    7.8%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

    0.2%

     

    14.5%

     

    2.2%

     

    0.1%

     

    N/A

     

    0.1%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Nine months ended

     

     

    September 27, 2025

     

    September 28, 2024

     

     

    Direct selling & Other

     

    Hiya direct-to-consumer

     

    Consolidated

     

    Direct selling & Other

     

    Hiya direct-to-consumer

     

    Consolidated

    Net sales

     

    100.0%

     

    100.0%

     

    100.0%

     

    100.0%

     

    N/A

     

    100.0%

    Cost of sales

     

    19.1%

     

    36.7%

     

    21.7%

     

    19.1%

     

    N/A

     

    19.1%

    Gross profit

     

    80.9%

     

    63.3%

     

    78.3%

     

    80.9%

     

    N/A

     

    80.9%

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Brand Partner incentives

     

    42.7%

     

    —%

     

    36.4%

     

    42.2%

     

    N/A

     

    42.2%

    Selling, general and administrative

     

    33.0%

     

    60.8%

     

    37.1%

     

    29.6%

     

    N/A

     

    29.6%

    Total operating expenses

     

    75.7%

     

    60.8%

     

    73.5%

     

    71.8%

     

    N/A

     

    71.8%

    Earnings from operations

     

    5.2%

     

    2.5%

     

    4.8%

     

    9.1%

     

    N/A

     

    9.1%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

    0.2%

     

    13.1%

     

    2.0%

     

    0.2%

     

    N/A

     

    0.2%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251022419409/en/

    Investor contact:

    Andrew Masuda

    Investor Relations

    (801) 954-7201

    [email protected]

    Media contact:

    Sarah Searle

    (801) 954-7626

    [email protected]

    Get the next $USNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Wentz Myron W gifted 145,000 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    9/5/25 10:13:30 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fuller Gilbert A sold $30,789 worth of shares (1,058 units at $29.10), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    8/8/25 2:22:21 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF SALES OFFICER Mulham David Mulham sold $106,364 worth of shares (3,515 units at $30.26), decreasing direct ownership by 28% to 9,260 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    7/31/25 11:03:26 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Updates the Timing of the Release of Third Quarter 2025 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow

    10/20/25 5:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA's Vitamin D Supplement Shines Bright with ConsumerLab.com Seal of Approval--Setting the Standard for Product Quality

    SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- USANA (NYSE:USNA), a global leader in cellular nutrition, is bringing a little more sunshine to wellness. Its top-rated Vitamin D supplement has officially earned the prestigious ConsumerLab.com Seal of Approval—a recognition reserved for products that deliver on purity, potency, and scientific precision. With approximately 42% of adults in the United States considered vitamin D deficient, having a vitamin D supplement on the market you can trust makes all the difference. "This isn't just a win for our product—it's a win for consum

    10/16/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    10/22/25 4:12:42 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    10/9/25 4:10:36 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SCHEDULE 13G filed by USANA Health Sciences Inc.

    SCHEDULE 13G - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    10/9/25 1:48:12 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Updates the Timing of the Release of Third Quarter 2025 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow

    10/20/25 5:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Provides Preliminary Third Quarter Results

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary results for the third quarter ended September 27, 2025. The Company anticipates third quarter 2025 net sales will be approximately $214 million, which compares with $200 million in the prior-year period. Earnings from operations are expected to be $1.2 million for the current-year quarter, or 0.6% of net sales, as compared to $15.6 million in the third quarter of 2024. "Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of our enhanced Brand Partner compensation plan," said Jim Brown, President and Chief Executive Office

    10/9/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Appoints New Chief Scientific Officer

    Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

    1/22/25 7:07:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

    SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

    7/1/24 7:13:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care